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To gain insightful information about the mechanisms through which genes are activated and repressed requires gene reporter systems that are sensitive, robust, and cost-effective. Although numerous reporter gene technologies are commercially available, none
are as sophisticated and user-friendly as β-lactamase (BLA) when it comes to studying gene expression in live cells. This article
presents an overview of the BLA technology and describes how it can be exploited for studying rare events such as homologous
recombination in somatic cells and be used to deliver any DNA sequence of choice anywhere within the genome.

INTRODUCTION
Over the past several years, the
combination of functional genomics,
proteomics, and bioinformatics has
contributed significantly to the identification of novel molecules that now
serve as valid targets for therapeutic
intervention against various diseases.
Rapid generation of lead compounds
that will inhibit or, in some cases,
potentiate the activities of these target
molecules necessitates the availability
of robust, sensitive, and cost-effective
assays. Previously, biochemical assays
were used more than cell-based assays,
but, due to emerging technologies,
this trend is changing, and the demand
for cell-based assays is gradually
increasing. Although biochemical
assays are well-defined, sensitive, and
easy to miniaturize, they are nonphysiological and require purified protein.
Moreover, biochemical assays can be
challenging to develop for difficult-topurify (but nonetheless therapeutically
important) proteins, such as membrane
receptors, ion channels, and G proteincoupled receptors (GPCRs). In contrast,
cell-based assays offer investigators the
luxury of probing biological activity
of a protein or a pathway in its natural

physiological milieu, and therefore are
closer to recapitulating the actual in
vivo situation.
CURRENT REPORTER GENE
DETECTION SYSTEMS
The success of cell-based assays
depends entirely on the quality of
the reporter gene. To date, numerous
reporter genes have been used for
monitoring gene expression (1). While
useful, most commercially available
reporter technologies are not versatile
enough to cover every aspect of cellbased assay development and screening
(see Table 1). For instance, although
luciferase-based assays provide
acceptable sensitivity and an excellent
dynamic range, they cannot be used
for fluorescence-activated cell sorting
(FACS), because the bioluminescent
emission produced after the breakdown
of D-luciferin is only transient. Thus,
deriving stable cell lines from single
cells expressing luciferase necessitates labor-intensive serial dilutions
and makes this system ill-suited for
cell-based assay development (1).
Secreted alkaline phosphatase (seAP)
is another reporter system in which

the expressed seAP is detected when it
activates a dioxetane derivative, which
decomposes and emits light during the
decomposition process. Like luciferase,
the seAP system is incompatible with
FACS, and developing seAP expressing
cell lines from single cells also requires
time-consuming and labor-intensive
serial dilutions. The oldest reporter
system, chloramphenicol acetyl transferase (CAT), requires a radioactive
substrate; this feature reduces its utility
for many researchers.
Another usable reporter gene is the
lacZ encoded enzyme β-galactosidase
(1). Historically, this reporter gene has
served as a valuable tool for cell and
developmental biologists. The activity
of β-galactosidase, comprised of a
homotetramer of 116-kDa subunits, in
a cell or fixed tissue can be monitored
colorimetrically with its substrate 5bromo-4-chloro-3-indolyl-β-d-galactopyranoside (X-gal), which produces
a blue precipitate upon cleavage. This
enzyme’s activity may also be detected
fluorometrically in live cells with
the synthetic substrate, fluoresceinβ-digalactopyranoside (FDG) (2).
Whereas the native substrate does not
fluoresce, β-galactosidase cleavage
of FDG produces free fluorescein
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Table 1. Characteristics of Gene Reporter Systems
Enzyme Amplification

Miniaturizable

Ratiometric

FACS-Compatible

Stable Cell Lines

β-Lactamase

+++

+++

+++

+++

+++

Luciferase

+++

++

—

—

+

Secreted AP

+++

+

—

—

+

CAT

+++

—

—

—

—

β-Galactosidase

+++

++

—

++

++

—

+

—

+++

+++

Reporter Gene

GFP

FACS, fluorescence-activated cell sorting; AP, alkaline phosphatase; CAT, chloramphenicol acetyl transferase; GFP, green fluorescent protein; +++, highly
appropriate; ++, appropriate; +, time-consuming or labor-intensive; —, inappropriate.

that can be detected in live cells by
epifluorescence microscopy or flow
cytometry. Although the β-galactosidase/FDG combination has been
used in FACS, it has shortcomings (3).
First, because FDG is polar, it does not
readily cross the plasma membrane.
To introduce FDG inside cells, they
must be subjected to a harsh hypotonic
shock procedure, which leads to
uneven substrate loading. Since
fluorescence signal intensity from the
cells depends on both enzyme and
substrate concentrations, it is affected
by uneven substrate loading. Second,
the free fluorescein produced by FDG
cleavage rapidly diffuses out of the
cell. To minimize this efflux, cells
must be kept on ice during the entire
loading period. Currently, no other
commercially available lipophilic

substrate exists that can readily cross
the cell membrane and quantitatively
report the expression levels of β-galactosidase within a cell. In spite of the
problems associated with the β-galactosidase/FDG system, it has been used
as a tool for studying protein-protein
interactions in live cells (4).
Green fluorescent protein (GFP)
from the jellyfish Aequorea victoria
is another commonly used reporter
system (5). The main advantage of GFP
is that it is noninvasive and inherently
fluorescent (i.e., it requires no substrate
for detection). In addition, using
different spectrally resolved mutants of
GFP enables an investigator to track the
expression of two (or more) genes in
the same cell (multiplexing). As a nonenzymatic reporter, however, GFP’s
limit of detection is approximately 105

molecules/cell. The low sensitivity of
GFP undermines its effectiveness as a
good reporter system.
β-LACTAMASE: A REPORTER
FOR ALL SEASONS
The β-lactamase reporter system
makes use of the enzyme TEM-1
β-lactamase (BLA), which lacks the
N-terminal 23 amino acid periplasmic
secretory signal sequence. BLA is a 29kDa enzyme encoded by the ampicillin
resistance gene (ampr) that is active
either as a monomer or when fused N or
C terminally to a heterologous protein
(6) and can cleave β-lactam-containing
molecules like penicillins and cephalosporins with simple kinetics and high
catalytic efficiency. No ortholog of

����������

Figure 1. Illustration of the β-lactamase reporter system. After an esterified (acetoxymethylated; AM) form of this substrate CCF2/4 (CCF2/4-AM) enters
a cell, endogenous esterases convert it to CCF2/4, thereby trapping it inside the cell. Exciting CCF2/4 at 408 nm leads to efficient FRET from the coumarin
moiety to the fluorescein derivative and produces green fluorescence detectable at 530 nm. After β-lactamase cleaves CCF2/4, the two fluorophores separate,
causing loss of fluorescence resonance energy transfer (FRET); excitation at 408 nm now results in blue fluorescence detectable at 460 nm.
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to the fluorescein derivative
and produces green fluorescence (λ = 530 nm) (Figure
2A). Cleavage of CCF2/4 by βlactamase, however, separates
the two fluorophores, causing
loss of FRET; excitation of
coumarin now results in blue
fluorescence (λ = 460 nm)
(Figure 2B). Thus, based on
the change in the color of
the fluorescence emission
B
signal, live cells expressing
BLA can be unequivocally,
simply, and rapidly (in as little
as 1 h) distinguished from
those that lack the enzyme by
epifluorescence microscopy,
fluorescent plate reader, or
flow cytometry.
In the BLA-CCF2/4
system, the green fluorescence observed immediately
Figure 2. Monitoring the expression of β-lactamase in
living cells. After loading the cells with an esterified (ace- after delivering (loading)
toxymethylated; AM) form of this substrate CCF2/4 (CCF2/4the substrate indicates that
AM), cells from which the enzyme TEM-1 β-lactamase (BLA)
the intact substrate has
is absent are green (A), whereas the BLA-expressing cells are
been successfully loaded in
seen as blue (B).
each cell. This unique and
powerful feature distinguishes
BLA from other reporter systems,
BLA exists in eukaryotes. Additionally,
in which registering delivery of the
overexpression of BLA is not accomsubstrate is impossible (e.g., loading
panied by any apparent toxicity in
the β-galactosidase substrate FDG
eukaryotic cells.
into cells). Equally important, the
The effectiveness of BLA as a
CCF2/4 substrate enables ratiometric
reporter gene was not realized until
data analysis (the ratio of the net blue
Zlokarnik and colleagues reported
fluorescence signal intensity and the
the synthesis of a fluorogenic BLA
net green fluorescence signal intensity;
substrate CCF2 (7). Another BLA
em. 460/em. 530), which eliminates
substrate, CCF4, is relatively more
problems arising from well-to-well
soluble than CCF2 in aqueous solutions
variations in cell number and fluoresand is therefore preferred over CCF2 for
cence signal intensity.
some applications. CCF2/4 is composed
Because neither BLA nor its
of two fluorescent dyes, 7-hydroxycousubstrate (intact or cleaved) is toxic,
marin-3-carboxamide and fluorescein,
this reporter system can be used to not
bridged by cephalosporin. The esterified
only monitor gene expression in live
(acetoxymethylated; AM) form of this
animals (8), but is also amenable for
substrate, CCF2/4-AM, is lipophilic
FACS, which can process as many as
and readily traverses cell membranes
104 cells/s (9). Consequently, the BLA
without stressing or damaging live
reporter system facilitates rapid develcells. As shown in Figure 1, once
opment of stably transfected clonal
CCF2/4-AM enters a cell, endogenous
cell lines. With the CCF2/4 substrate,
esterases convert it to CCF2/4. Because
as few as 50 molecules BLA can be
CCF2/4 is negatively charged at physidetected within a cell (7). This combiological pH, it becomes trapped inside
nation of enzymatic fluorescence signal
the cell. CCF2/4 can be easily detected
amplification and ratiometric data
by fluorescence resonance energy
analysis produces exquisitely sensitive
transfer (FRET). In the intact molecule,
and specific BLA-based assays that are
excitation of coumarin at 408 nm leads
ideally suited for ultraminiaturizable
to efficient FRET (quantum yield 0.74)
Vol. 42 ı No. 1 ı 2007

high-throughput screening (HTS)
applications (10).
Besides being useful as a traditional
reporter that allows easy monitoring
of signaling pathways in live cells (6),
BLA-based cell-based assays have
been developed for various classes of
gene families including GPCRs and
nuclear hormone receptors (11–15).
This biosensor has also been used for
studying protein folding (16), adaptive
and targeted gene evolution (17,18),
protease activity (19), gene trapping
(20,21), fusion of human immunodeficiency virus (HIV) virions to primary
CD4+ T lymphocytes (22,23), RNA
splicing (24), and protein-protein
interactions by fragment complementation (25–28). In one report, the BLA
reporter system was used for identifying inhibitors of hepatitis C viral
replication (29).
In spite of its many attractive features,
some of the shortcomings associated
with the BLA-CCF2/4 system are
that it has poor dynamic range and its
substrate CCF2/4 has a high molecular
weight and poor solubility in aqueous
solutions. In light of this, there is a
need for superior new-generation BLA
substrates, such as CC1 (30), that will
further improve the quality and effectiveness of this reporter.
DEVELOPING A
GLUCOCORTICOID RECEPTOR
CELL-BASED ASSAY WITH
β-LACTAMASE USING
ONE-ARM HOMOLOGOUS
RECOMBINATION
A member of the nuclear receptor
superfamily, the glucocorticoid receptor
(GR) is a ligand-activated transcriptional regulator. GR mediates glucocorticoid action that controls carbohydrate,
protein, and fat metabolism, suppresses
the immune/inflammatory responses,
regulates cardiovascular function,
and affects basal and stress-related
homeostasis. Glucocorticoid therapies
are used to treat asthma, chronic
arthritis, inflammatory bowel disease,
lymphoma, leukemia, hyperglycemia,
renal and pulmonary conditions,
multiple sclerosis, and headaches.
Since BLA permits an investigator
to isolate a single cell expressing the
www.biotechniques.com ı BioTechniques ı 93
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enzyme from a population, it should
be the system of choice for monitoring
rare events, such as homologous
recombination in somatic cells that
occurs at a very low frequency. That
the BLA reporter system is versatile
enough to be used for this purpose is
demonstrated by the fact that a robust
and sensitive GR cell-based assay
was developed using a novel one-arm
homologous recombination-based
approach in HEK 293T cells; the
details of how this was carried out are
described in Reference 13. Briefly, a
3.6-kb region spanning the 3′ end of
exon 5 to the middle of intron 6 of the
GR gene was amplified by PCR. This
fragment was then cloned immediately downstream of the GAL4-DNA
binding domain (GAL4-DBD; amino
acids 1–147), such that the 151 amino
acid of the resulting fusion protein
represents the 500th amino acid of
GR, which in turn corresponds to
the first amino acid of the GR ligand
binding domain (LBD) that spans
from amino acid 500–777 (31). The
three amino acids at positions 148,
149, and 150 arise from the plasmid
polylinker codons. The plasmid was
designed in such a way that, after
transfection, a precise homologous
recombination event would culminate
in the production of the GAL4(DBD)GR(LBD) from the strong cytomegalovirus (CMV) promoter. After
digestion with a restriction enzyme,
the linearized plasmid was used to
transfect 100 million HEK 293T
cells, which had previously been
stably transfected with a BLA reporter
plasmid under the control of an
upstream activating sequence (UAS)
containing seven GAL4-DBD binding
sites (plasmid referred to as pUASGal4BLA). The transfection efficiency was
estimated to be 0.2%. To identify stably
transfected cells in which the targeted
plasmid had integrated accurately, the
cells were starved for 24 h and then
treated with 1 μM dexamethasone,
a GR ligand, for 16 h. Subsequently,
100 million cells were loaded with
CCF2-AM from which 500,000 BLApositive cells were recovered by FACS.
After eliminating cells constitutively
expressing BLA from this pool, the
cycle of starving cells, treating them
with dexamethasone, loading them
94 ı BioTechniques ı www.biotechniques.com

with CCF2-AM and FACS sorting was
repeated twice. From the final FACS,
about 300 intense blue single cells
were collected in individual wells of
a 96-well plate from which approximately 200 survived. To obtain cell
lines highly responsive to dexamethasone, each of the expanded 200
transgenic clonal cell lines was characterized further. This exercise led to the
identification of several cell lines that
were validated by reverse transcription
PCR (RT-PCR) to ascertain that the
targeting vector had integrated at the
appropriate locus (this analysis made
use of two primers—one designed to
anneal within the GAL4-DBD region
and the other to an endogenous GR
exon not cloned in the construct).
Western blot analysis on extract
prepared from one of the cell lines with
α-GAL4-DBD antibody revealed the
presence of a 427 amino acid chimeric
GAL4(DBD)-GR(LBD) protein with a
molecular weight of 46 kDa.
This GR cell-based assay engineered
by homologous recombination exhibits
an excellent dynamic range; treating
the engineered HEK 293T cells first
with 1 μM dexamethasone for 16 h
and then loading with CCF4-AM for
1 h results in a >13-fold induction of
BLA expression. Moreover, the high
Z′ factor value (0.83) demonstrates the
robustness of the GR assay. Since the
assay is fully miniaturizable and has
been found to perform equally well
in 384- to 3456-well plates, it should
serve as a useful tool for drug hunters.
Development of the GR assay using
homologous recombination demonstrates that such assays can indeed be
developed using the BLA technology.
Additionally, this powerful approach,
which allows an investigator to insert
a DNA sequence anywhere in the
genome, is equally useful for introducing an affinity tag, overexpressing
a gene, or producing a transgenic
knockout cell line.
CONCLUSION
The BLA reporter system outshines
other reporter gene technologies in
terms of its sensitivity, robustness,
ease-of-use, and because it can be used
for studying gene expression in living

cells. It is for these reasons that this
technology serves as an excellent tool,
not only academic laboratories engaged
in basic research, but also for research
scientists in industry who are in the
business of developing cost-effective
and miniaturizable cell-based assays.
From the competing reporter gene
technologies, no other system offers a
FACS-compatible, ratiometric, HTSready technology.
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